ADHD &amp; Addiction:Prevalence, diagnostic assessment and treatment of ADHD in substance use disorder patients by van Emmerik-van Oortmerssen, Katelijne
  
 University of Groningen
ADHD & Addiction
van Emmerik-van Oortmerssen, Katelijne
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Emmerik-van Oortmerssen, K. (2018). ADHD & Addiction: Prevalence, diagnostic assessment and
treatment of ADHD in substance use disorder patients. [Groningen]: Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Katelijne van Emmerik-van Oortmerssen, Matthijs Blankers, Ellen Vedel, Floor J. 
Kramer, Anneke Goudriaan, Wim van den Brink, Robert A. Schoevers. 
In preparation for submission.
CHAPTER 11
PREDICTION OF DROP-OUT AND OUTCOME 
IN INTEGRATED COGNITIVE BEHAVIORAL 
THERAPY FOR ADHD AND SUD: RESULTS 
FROM A RANDOMIZED CLINICAL TRIAL. 
ABSTRACT
Background: Patients with substance use disorder (SUD) or Attention Deficit Hyperactivity Disorder 
(ADHD) have a high risk of drop-out from treatment, partly due to the nature of these disorders. Drop 
out is increased when these conditions co-occur and has a large effect on therapy outcome. Few 
studies have investigated predictors of therapy drop-out and outcome in SUD patients with comorbid 
ADHD. Recently, integrated cognitive behavioral therapy (CBT/Integrated) was shown to be more 
effective than standard CBT (CBT/SUD) in the treatment of SUD+ADHD, with better outcomes for CBT/
Integrated in terms of ADHD symptom reduction. 
Objective: To investigate the association of demographic, clinical and neurocognitive variables with 
drop-out and treatment outcome, and to examine which of these variables are suitable for patient-
treatment matching.
Methods: We performed an RCT in which 119 patients were allocated to CBT/Integrated (n=60) or CBT/
SUD (n=59). In addition, 55 patients had dropped out before randomization. Demographic variables 
(gender, age, level of education, employment status and relationship status), clinical characteristics 
(ADHD subtype and symptom severity, primary substance of abuse and SUD severity, depression 
and anxiety symptoms, the use of ADHD medication), and measures of cognitive functioning (Stroop, 
Tower of London (ToL) and Balloon Analogue Risk Task (BART)) were included as predictors. Outcome 
measures were: early treatment drop-out, ADHD symptom severity (ADHD rating scale), and substance 
use severity (Time Line Follow Back) at end of treatment and follow up.  
Results: Primary substance of abuse (drug use disorder as opposed to alcohol use disorder only) 
and lower accuracy scores on the ToL were significant predictors of early treatment drop-out in the 
multivariable analysis. Having more depression and anxiety symptoms at baseline and using ADHD 
medication at baseline significantly predicted more ADHD symptoms at end of treatment, and higher 
accuracy scores on the ToL significantly predicted higher substance use at end of treatment. No 
significant predictor by treatment interactions were found.  
Conclusion: The results add to the existing evidence that also relatively mild cognitive deficits are a risk 
factor for treatment drop-out in these patients. In addition, having more (severe) clinical symptoms at 
baseline predicted worse clinical outcomes at the end of treatment. None of the evaluated baseline 
variables differentially predicted outcome for the specific treatments and thus none of the variables 
were relevant for patient-treatment matching.
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INTRODUCTION
Substance use disorders (SUDs) are among the leading causes of morbidity and mortality 
worldwide.1,2 They cause a great deal of personal suffering for patients and their loved 
ones and have devastating medical, social and economic effects.3 Patients with SUD often 
have psychiatric comorbidities with adult Attention Deficit Hyperactivity Disorder (ADHD) 
being one of the most frequently encountered comorbid disorders.4,5 Although evidence-
based pharmacological and psychotherapeutic interventions for both SUD and ADHD are 
available, very little is known about the efficacy of treatment for patients with both conditions. 
Standard pharmacological treatment has shown mainly negative outcomes,6-10 but with two 
studies suggesting positive effects of high doses of stimulants.11,12 Recently, we have shown 
that integrated cognitive behavior therapy (CBT/Integrated) directed at both SUD and ADHD 
is more effective in these patients than standard CBT directed at SUD only (CBT/SUD).13 
However, many patients dropped out from treatment and there was no difference between 
treatments in substance use outcome. An important question is whether it can be predicted 
which patients with SUD and ADHD are more likely to drop out of treatment, with a higher 
chance of negative outcomes.
Predictors of treatment drop-out and treatment outcome in SUD treatment
Predictors of treatment drop-out in SUD treatment
Treatment completion has been proposed as an important factor related to favorable 
outcomes of addiction treatment. Treatment drop-out is common with reported drop-
out rates ranging from about 20% to 60%.14 In a systematic review, Brorson et al.14 found 
conflicting results for a range of patient, treatment and process characteristics, but 
consistent findings for cognitive deficits, low treatment alliance, comorbid personality 
disorder (antisocial/histrionic) and younger age. The link between treatment adherence 
and general cognition has been confirmed in many studies.15 This is important because 
many SUD patients may suffer from (mild) neurocognitive impairments16 either as a pre-
existing risk factor or as a result of chronic alcohol and/or drug use. In alcohol dependent 
patients for instance, deficits on neuropsychological tests are present in 50-80%.17 These 
impairments interfere with retention in and outcome of SUD treatment as they affect the 
ability to learn new information, integrate new skills and plan and implement behavioral 
strategies as alternatives to substance use.18 Only very few studies have examined 
treatment-related factors such as treatment method19 or treatment intensity20 as predictors 
of drop-out and therefore no firm conclusion can be drawn on this subject. In addition, 
several studies have found that drop-out in different treatment modalities was moderated 
by certain demographic risk factors such as age.14
Predictors of treatment outcome in SUD treatment
Treatment outcome (including abstinence and reduced substance use) is – amongst others 
- predicted by impairments in decision-making (Iowa Gambling Task), attentional bias and 
baseline impulsivity.15,21,22 Interestingly, Passetti et al. found that deficits in decision making 
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only influenced outcome in an outpatient setting, but not in inpatients.23 
Predictors of treatment drop-out and outcome in ADHD treatment
Predictors of treatment drop-out in ADHD treatment
In contrast to the many studies on drop-out from addiction treatment, relatively little is 
known about factors involved in treatment drop-out in patients with adult ADHD. Studies 
have mainly focused on medication non-adherence, which is reported to be around 50%.24 
Factors associated with medication non-adherence include age,25-27 gender,27 comorbid 
psychiatric disorders ,25,27-30 and medication related factors such as type of medication,24 
adverse effects, 24-26,31,32 and lack of efficacy.25,32 In several trials on CBT for ADHD patients, 
drop-out rates were very low,33,34 but no information was reported on factors associated 
with drop-out. 
Predictors of treatment outcome in ADHD treatment
Although several authors argue that in the future, genetic information35 and neurocognitive 
measures36 may be used in the prediction of pharmacological treatment response and 
in personalizing treatment for ADHD, this is not yet the case. To date, the literature on 
predictors of treatment outcome and patient-treatment matching in ADHD is very limited. 
Comorbidity of ADHD with SUD and with personality disorders was associated with lower 
treatment response in methylphenidate treatment in a study by Retz et al.37 With regard to 
predictors of psychological treatment for (adult) ADHD there are even fewer studies. We 
found only one study that explored treatment matching of CBT programs for adolescents 
with ADHD, where a planning intervention outperformed solution focused therapy in a 
subgroup of patients with comorbid anxiety symptoms but low depression levels.38 
Predictors of drop-out and outcome in the treatment of SUD + ADHD patients
Several studies report that comorbid ADHD is associated with less optimal outcomes in SUD 
treatment.39 However, very little is known about risk factors related to drop-out or treatment 
outcome in SUD + ADHD patients.  We found one study among adolescents with SUD and 
ADHD that showed  substance use, ADHD symptom severity at baseline, conduct disorder, 
and count-mandated status to be related to outcome,40 but no such data on adults were 
found. 
When summarizing the existing literature, we conclude that although many studies have 
looked at predictors for drop-out and outcome in SUD patients, there is only minimal 
information on predictors of drop-out and outcome in SUD + ADHD patients. In a recent 
RCT we showed that CBT/Integrated is effective in reducing ADHD symptoms.13 Still, we 
do not know whether this treatment is equally effective for all patients, or whether certain 
patient characteristics differentially affect treatment outcome. Finally, we found no overall 
difference on SUD outcome between the treatments, but differential benefits may exist 
for certain patient groups and the lack of an overall effect may be the result of opposing 
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outcomes in different subgroups, i.e. some of the patients getting better and others getting 
worse with the new treatment. Therefore, the current study first examined the predictive 
value of demographic variables, clinical characteristics and aspects of cognitive functioning 
on overall treatment drop-out of patients with SUD and ADHD. Second, we examined which 
patient characteristics were associated with a positive treatment outcome in CBT/Integrated. 
Additionally, we examined whether certain variables differentially predicted outcomes of 
CBT/Integrated compared with CBT/SUD (patient-treatment matching). 
METHODS
Design
This study was designed as an open-label, parallel-group, randomized controlled trial. 
After screening and baseline assessment, participants were randomly assigned to the 
experimental group (CBT/Integrated, consisting of 15 CBT sessions to treat SUD and ADHD) 
or the control group (CBT/SUD, consisting of 10 CBT sessions to treat SUD). Randomization 
was performed by online application of a biased-coin randomization, aiming to balance trial 
arms with respect to gender, SUD diagnosis (alcohol only versus other substances), and the 
use of ADHD medication (yes/no). For detailed information about the procedure, see van 
Emmerik-van Oortmerssen et al.41 
The study was approved by the medical ethics committee of the Academic Medical Centre in 
Amsterdam and all participants provided written informed consent. The study is registered 
in the Clinical Trial Register (www.clinicaltrials.gov NCT01431235). 
Participants
Eligible patients were referrals seeking treatment for substance use problems at the Jellinek, 
a large addiction treatment center in Amsterdam, The Netherlands. Inclusion criteria were: 
age 18-65 years, full command of the Dutch language, current DSM-IV diagnosis of any 
substance use disorder other than only nicotine dependence, a comorbid DSM-IV diagnosis 
of adult ADHD, and after intake allocated to outpatient treatment. Patients were excluded 
if they suffered from a severe neurological or psychiatric disorder (e.g. psychosis), or if they 
had a comorbid diagnosis of borderline personality disorder. 
Procedure 
New patients were assessed for eligibility in the intake procedure. Then, at inclusion, baseline 
data were collected. Subsequently, participants started with Phase I of treatment, which 
consisted of the first four CBT treatment sessions, all of which were aimed at the treatment 
of SUD. Then, randomization took place for Phase II of the treatment, including either 11 
sessions CBT/Integrated or 6 sessions CBT/SUD). At the end of treatment, post-treatment 
measures were administered, and follow-up measures were performed two months later.  
The order of the test administration was the same for all participants. Abstinence from 
alcohol or drugs was no prerequisite to participate. 
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A total of 174 patients were included in this study; their data were used in the analyses 
of early Phase I drop-out  (which comprises the first four treatment sessions, i.e. before 
randomization took place). A total of 119 patients were randomized and included in the 
treatment outcome analyses. In the original RCT, 184 patients were included, 10 of whom 
were neither early drop-outs nor randomized for different reasons; their data  were not 
used in this study. 
Treatments
CBT/Integrated consisted of 15 individually-delivered weekly CBT sessions. The outline of 
the treatment protocol is published elsewhere.41 Every session dealt with a predefined 
topic, with 5 sessions on ADHD-related topics, and 10 sessions for the treatment of SUD. 
CBT/SUD consisted of these 10 sessions for the treatment of SUD only. In both treatments, 
the first 4 sessions (Phase 1 of treatment) were the same and dealt with SUD treatment 
only. Both treatments were provided by trained, experienced therapists. 
Assessments/ measures
Eligibility
The Composite International Diagnostic Interview (CIDI)42 was used for diagnostic assessment 
of SUD, the first six items of the Adult ADHD Self-Report Scale (ASRS-v1.1)43  were used 
to screen patients for ADHD, and Conners’ Adults ADHD Diagnostic Interview for DSM-IV 
(CAADID)44 was used to diagnose ADHD. 
Predictors
• Sociodemographic data on age, gender, job status, highest educational level and 
relationship status were retrieved at baseline. 
• Type of SUD (alcohol only, or other) was determined according to the CIDI.
• Subtype of ADHD was determined according to the CAADID.
• Information on the use of ADHD medication (yes/no) at baseline was obtained.
• Baseline severity of ADHD symptoms were assessed with the ADHD rating scale.45
• Severity of alcohol and drug use in the two months before referral to treatment was 
measured using the Time Line Follow Back (TLFB) procedure.46 From this measure, only 
the number of days with heavy use in the past week was used. Heavy use was defined as 
at least six standard units of alcoholic beverages for men per day, at least four for women 
(in the case of alcohol as the primary drug of abuse), more than one joint per day (in the 
case of cannabis being the primary drug of abuse), or any use of other illicit drugs.
• Depressive and anxiety symptoms at baseline were assessed with the Beck Depression 
Inventory (BDI)47 and the Beck Anxiety Inventory (BAI).48
• Spatial planning abilities were measured with a computerized Tower of London (ToL) 
task.49 In this task, the participant had to sort balls of three different colors on sticks of 
different lengths into a specified pattern. In the computerized version, the balls cannot 
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actually be moved, but for each trial the participant had to plan and count how many 
steps are necessary to place the balls in a correct way. The complexity of the task differed 
from one to six steps. Patients had a limited time of 60 seconds to answer each trial. The 
main outcome variable of this task was the accuracy or the number of correct responses, 
calculated as a weighted sum that takes into account the difficulty of each trial. In addition, 
latency or average time needed per trial to give a response was used (reaction time). 
• Cognitive interference and selective attention was measured with a computerized 
version of the classic Color-Word Stroop task.50,51 In this task, congruent color words 
and incongruent color words (e.g. the word ‘red’ written in green ink) were presented; 
participants were instructed to respond via the keyboard, as quickly and accurately as 
possible, to the color in which each word was printed, while attempting to ignore reading 
the word. The interference score was calculated by subtracting the mean reaction time 
on the congruent stimuli from the mean reaction time on the incongruent stimuli for 
all correct trials. In addition, accuracy (i.e. the percentage of correct responses) on the 
congruent trials and accuracy on the incongruent trials were used.  
• Risk taking propensity, conceptualized as the interaction between poor impulse control 
and heightened reward seeking,52 was assessed with the Balloon Analogue Risk Task 
(BART).53 In this computerized task, risky choices lead to positive consequences to a 
certain point, with further excessive risk taking leading to greater negative consequences. 
In this task, a small balloon was presented, which could be inflated by pressing on the 
balloon pump. With each pump, money (5 cents) was accumulated in a temporary 
bank, but when the balloon exploded, all money in the temporary bank was lost. Twenty 
balloons were presented and for each balloon the participant had to decide when to 
stop pumping and collect the money from the temporary bank into the permanent bank. 
Each balloon had the probability to explode between 1 and 128 pumps with an average 
breakpoint of 64 pumps; participants were simply informed that the balloon could break 
anywhere from the first pump all the way through enough pumps to make the balloon 
fill the screen. Participants were asked to try and earn as much money as possible and 
were informed that the money would not really be paid. The measure that we used from 
this task was the average number of pumps used only on balloon trials that were banked, 
excluding those balloons that exploded.53   
Outcome variables
Phase I drop-out  (treatment session 1-4, before randomization) and treatment outcomes 
(ADHD symptom severity and alcohol/drug use according to the TLFB at post-treatment and 
follow-up) were used as dependent variables for the various research questions. 
Data analysis
Between-group (experimental versus control) differences in baseline characteristics were 
analyzed using Chi-square tests for dichotomous variables and independent t-tests for 
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continuous variables. The continuous variables age, depression symptoms and anxiety 
symptoms have been mean centered before analysis. 
For the first research question, addressing the prediction of phase I drop-out, we used 
univariate logistic regression analyses. Predictors that were significantly associated with 
drop-out (p<.10) were also included in a multiple logistic regression model. For these 
analyses, a total of 174 patients were available, including 55 patients that dropped out in the 
allocated time frame. 
For the second research question, addressing the prediction of outcomes in CBT/Integrated 
(n=60), we used Generalized Linear Mixed Model regression analysis (GLMM). To model 
baseline variance in the GLMM, we fitted a random intercept model in which the scores on 
the outcome measures at outcome and follow-up were used as the dependent variable. 
The predictors were added to the model; for each predictor a model was specified using 
the R package lme4 [https://cran.r-project.org/web/packages/lme4/citation.html] as follows: 
[Dependent ~ 1 + Predictor + (1|ParticipantId)]. In  this analysis, no distinction could be 
made between the outcome at post-treatment and 2-month follow-up.  
Finally, GLMM was also used to explore patient-treatment matching. In these analyses, both 
patients randomized to CBT/Integrated and patients randomized to CBT/SUD were included 
(n=119). The predictors, condition, and predictor X condition terms were added to the model; 
for each predictor a model was specified using the R package lme4 [ https://cran.r-project.
org/web/packages/lme4/citation.html] as follows: [Dependent ~ 1 + Predictor*Condition + 
(1|ParticipantId)].
Analyses were performed with Microsoft R open version 3.4.0; using the package lme4 for 
the GLMM analyses. Alpha was set at α=0.05, two-sided. 
There were missing data at baseline due to logistic reasons (mostly because patients did not 
longer want to continue the assessment) on the BART for 2 patients, on the Stroop task for 
2 patients and on the ToL task for 27 patients (the ToL was the last task of the assessment; 
a considerable amount of patients wanted to leave before they finished the full test battery). 
In CBT/Integrated, 48 out of 60 patients participated in the post-treatment assessment, and 
39 patients in the follow-up assessment, resulting in 87 observations for the GLMM analyses 
on prediction of outcome/follow-up. In CBT/SUD, 46 out of 59 patients participated in the 
post-treatment assessment and 39 in the follow-up assessment, resulting in a total of 172 
observations for patient treatment matching analyses. 
RESULTS
Baseline characteristics
Table 1 shows the baseline demographic, clinical and neurocognitive characteristics of the 
participants. 119 patients were randomized to either CBT/Integrated (n=60) or CBT/SUD 
(n=59). Fifty-five of the 174 eligible patients dropped out of treatment before randomization 
took place. 
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Table 1: Baseline sociodemographic, clinical and neurocognitive characteristics: number, 
percentage or mean and standard deviation (SD). 
All randomized 
patients (n=119)








Age in years (SD) 35.1 (8.9) 33.3 (8.5) 35.4 (8.8) 34.7 (9.1) .675
Gender, No. male (%) 99 (83.2) 49 (89.1) 50 (83.3) 49 (83.1) .967
Married/ cohabitant (%) 46 (38.7) 18 (32.7) 27 (45.0) 19 (32.2) .154
Job status, No. employed (%) 95 (79.8) 37 (67.2) 47 (78.3) 48 (81.3) .820
Education: highest completed education 
level, No. (%)
N=118 N=53 N=59
  Low 14 (11.9) 13 (24.5) 9 (15.3) 5 (8.5)
.348
  Average 39 (33.1) 24 (45.3) 17 (28.8) 22 (37.3)
  Higher 49 (41.5) 15 (28.3) 27 (45.8) 22 (37.3)
  Highest 16 (13.6) 1 (1.9) 6 (10.2) 10 (16.9)
Primary substance of abuse, No. (%)
  Alcohol only 31 (26.1) 2 (3.6) 16 (26.7) 15 (25.4) .877
Substance use severity: number of days of 
excessiveb use in past week (SD)
2.88 (2.7) 3.8 (2.9) 2.6 (2.6) 3.2 (2.8) .179
ADHD diagnosisc, No. (%) 
  Inattentive subtype 63 (52.9)
N.A.
33 (55.0) 30 (50.8)
.895  Hyperactive/ impulsive subtype 10 (8.4) 5 (8.3) 5 (8.5)
  Combined subtype 46 (38.7) 22 (36.7) 24 (40.7)
ADHD rating scaled (SD) 31.8 (6.8) 30.3 (7.5) 31.5 (6.3) 32.2 (7.3) .574
Beck Depression Inventorye (SD) 16.4 (8.4) 16.3 (8.6) 16.1 (8.8) 16.8 (8.1) .647
Beck Anxiety Inventoryf (SD) 13.9 (8.8) 14.9 (8.5) 14.4 (9.0) 13.4 (8.5) .547
Use of ADHD medication at baselineg, 
No. (%)
5 (4.2) 3 (5.5) 4 (6.7) 1 (1.7) .177
ToL: accuracy 118.3 (20.4) 
(n=101)















Stroop: interference 95.8 (141.6) 95.6 (118.8) (n=53) 72.6 (105.5) 119.0 (167.0) .075
Stroop: accuracy congruent trials .98 (.02) .97 (.04) (n=53) .98 (.03) .99 (.02) .044
Stroop: accuracy incongruent trials .94 (.17) .93 (.15) (n=53) .96 (.13) .93 (.20) .403
BART: Adjusted Average Pumps 36.6 (12.2) 
(n=118)
33.2 (12.2) (n=54) 36.6 (13.0) (n=59) 36.6 (11.5) .993
Note:
• Abbreviations: ADHD,  Attention Deficit Hyperactivity Disorder; CBT/Integrated, Integrated Cognitive Behavioral Therapy; CBT/SUD, 
Cognitive Behavioral Therapy for Substance Use Disorders. 
• a P value indicates comparison of patients in CBT/Integrated and CBT/SUD (t-test or Chi-square tests)
• b Excessive use is defined as ≥ 6 standard units a day in the case of alcohol for men, and ≥ 4 for women; > 1 joint a day in the case of 
cannabis, and any use on a day in the case of another drug. 
• c At randomization
• d,e,f Higher scores indicate more severe symptoms
• g 3 patients started medication after post-treatment measurements (2 patients in CBT/Integrated and 1 patient in CBT/SUD), apart from 
the patients that are reported in this table. 
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Prediction of phase I drop-out
Table 2 shows that the following predictors were associated with fewer early drop-outs 
(p<0.10): higher level of education, being employed, alcohol as only SUD, higher accuracy 
and reaction time score on the ToL, higher accuracy on congruent trials in de Stroop task, 
and higher scores on the BART. In the multivariate model in which these variables were 
included, only type of SUD (OR=15.99, C.I.=2.73-315.75, p=.012) and accuracy on the ToL 
(OR=0.98, C.I.=0.95-1.00, p=.045) remained as significant (p<0.05) independent predictors. 
Table 2. Predictors of early drop-out from cognitive behavioral treatment: results of 
univariate regression analyses.
Odds Ratio Confidence Interval p-value 
Age 0.98 0.94 – 1.01 .218
Gender (women, with men as reference) 0.00 N.A. .997
Married/ cohabitant (yes versus no) 0.79 0.40 – 1.55 .505
Job status (employed vs unemployed) 0.52 0.25 – 1.07 .074
Educational level (low as reference)
  Average 0.66 0.27 – 1.66 .376
  Higher 0.33 0.13 – 0.85 .022
  Highest 0.07 0.00 – 0.40 .014
Primary substance of abuse (other substance, with alcohol 
only as reference) 9.34 2.67 – 59.12 .003
Substance use severitya (past week) 1.13 1.01 – 1.27 .039
ADHD rating scale 0.97 0.92 – 1.01 .176
Beck Depression Inventory 1.00 0.96 – 1.04 .928
Beck Anxiety Inventory 1.01 0.98 – 1.05 .473
Use of ADHD medication (yes versus no) 1.32 0.26 – 5.57 .715
ToL: accuracy 0.97 0.95 – 0.99 .003
ToL: reaction time 1.00 0.9998 – 1.0000 .041
Stroop: interference 1.00 1.00 – 1.00 .992
Stroop: accuracy congruent trials 0.00 0.000 – 0.053 .021
Stroop: accuracy incongruent trials 0.67 0.10 – 5.53 .681
BART: Adj Avg Pumps 0.98 0.95 – 1.00 .091
Note:
• Abbreviations: SUD: Substance Use Disorder; ADHD: Attention Deficit Hyperactivity Disorder ToL: Tower of London; 
BART: Balloon Analogue Risk Task.
•  a excessive use, defined as ≥ 6 standard units a day in the case of alcohol for men, and ≥ 4 for women; > 1 joint a day 
in the case of cannabis, and any use on a day in the case of another drug. 
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Prediction of outcome in CBT/Integrated
Prediction of ADHD symptoms
More baseline depressive symptoms and anxiety symptoms were significantly associated 
with more ADHD symptoms at post-treatment /follow-up (p<.001). The use of ADHD 
medication at baseline was also significantly associated with more ADHD symptoms at post-
treatment/ follow-up (p=.003) (see Table 3). 
Table 3: Predictors of ADHD and SUD symptom severity outcome in CBT/Integrated: results 
from Generalized Linear Mixed Models.
ADHD symptoms outcome Substance use severity outcome
Beta P value Beta P value
Age 0.11 .413 -0.21 .364
Gender (women, with men as reference) 0.05 .737 0.16 .426
Married/ cohabitant (yes versus no) 0.07 .615 -0.00 .974
Job status (employed vs unemployed) -0.10 .482 -0.16 .195
Educational level (low as reference)
  Average 0.20 .367 0.47 .199
 Higher 0.20 .366 0.38 .328
 Highest 0.05 .802 0.37 .215
Primary substance of abuse (other substance, 
with alcohol only as reference)
0.03 .845 -0.08 .710
Substance use severitya past week -0.01 .958 N.A. N.A.
ADHD subtype (inattentive as reference)
 Hyperactive/impulsive 0.12 .382 0.04 .815
 Combined 0.14 .329 -0.31 .123
ADHD rating scale N.A. N.A. -0.21 .086
Beck Depression Inventory 0.38 <.001 -0.10 .544
Beck Anxiety Inventory 0.46 <.001 0.19 .303
Use of ADHD medication (yes versus no) 0.35 .003 -4.11 1.00
ToL: accuracy -0.03 .837 0.14 <.001
ToL: reaction time -0.07 .644 N.A. b N.A. b
Stroop: interference -0.01 .954 0.12 .581
Stroop: accuracy congruent trials -0.03 .801 0.25 .261
Stroop: accuracy incongruent trials 0.00 .998 -0.12 .517
BART: Adj Avg Pumps 0.06 .668 -0.11 .559
Note:
• Abbreviations: SUD: Substance Use Disorder; ADHD: Attention Deficit Hyperactivity Disorder ToL: Tower of London; 
BART: Balloon Analogue Risk Task.  
•  a excessive use, defined as ≥ 6 standard units a day in the case of alcohol for men, and ≥ 4 for women; > 1 joint a day 
in the case of cannabis, and any use on a day in the case of another drug.
•  b ToL reaction time was not included in these analysis because of convergence problems.
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Prediction of substance use
Only accuracy on the ToL was significantly associated with substance use at post-treatment/ 
follow-up, with lower accuracy scores related to lower substance use at outcome (p<.001) 
(see Table 3).
Patient-treatment matching
No significant predictor by treatment interactions were found, neither for ADHD nor SUD 
outcomes (results not shown). This means that there were no patient characteristics 
predicting a clear benefit of CBT/Integrated over CBT/SUD or vice versa.   
DISCUSSION
This study examined the role of different patient factors (socio-demographic factors, 
clinical characteristics and cognitive functioning) as predictors of early drop-out from CBT 
treatment, as predictors of treatment outcome in CBT/Integrated, and as candidates for 
patient-treatment matching to either CBT/Integrated or CBT/SUD. 
The results indicated that a lower level of education, unemployment, drug use problems, 
substance use severity, lower accuracy and shorter reactions times on the ToL, lower 
accuracy on congruent trials of the Stroop, and a lower BART score were associated with 
higher drop-out from CBT treatment in Phase I (p<.10). Type of SUD (drugs vs alcohol) 
(OR=15.99, C.I.=2.73-315.75, p=.012) and accuracy on the ToL (OR=0.98, C.I.=0.95-1.00, 
p=.045) however were the only independent predictors in the multivariate model. This 
means that for a patient with a drug use disorder the odds of dropping out of treatment 
are 9 times higher than for a patient with an alcohol use disorder, and for a single point 
higher result on accuracy of the ToL, the chance of dropping out is 3% lower, according to 
the results of the bivariate analyses. Our finding regarding the ToL is in line with many other 
studies demonstrating that impaired cognitive functioning is a predictor of early drop-out 
from addiction treatment.15 We did not find other studies distinguishing between alcohol 
and drugs in terms of drop-out. We found no association between the results on the Stroop 
task and treatment drop out, in contrast to two other studies, in which a modest association 
between Stroop effect and SUD treatment retention was found.54,55 Possibly, in this group 
of SUD patients with comorbid ADHD, inattention and thus interference problems were 
present to some extent in all participants and had no discriminative value. 
With regard to the prediction of treatment outcome in CBT/Integrated, we found that fewer 
baseline depression and anxiety symptoms and not using ADHD medication at baseline 
predicted  lower ADHD scores at outcome. Possibly, the severity of ADHD symptoms was 
higher in medicated patients from baseline on, which could explain the positive association 
at outcome. This also holds for comorbid depressive and anxiety symptoms, which may 
have been highest in patients with severe ADHD symptoms. Only lower accuracy scores 
on the baseline ToL predicted lower substance use scores at outcome. We do not have an 
explanation for this counterintuitive finding, which is also inconsistent with our finding that 
lower accuracy on the ToL predicted higher early drop-out.  
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Finally, we demonstrated that no patient characteristics were associated with a benefit of 
CBT/Integrated over CBT/SUD or vice versa, meaning that the benefit of CBT/Integrated is 
not limited to a specific subgroup of SUD patients with ADHD. 
This was the first study to explore potential predictors for drop-out, outcome and patient-
treatment matching in CBT/Integrated, but also in psychotherapies in adult SUD patients 
with ADHD in general. Quite a large number of patients participated in this study, and 
information was collected on a large range of potential relevant factors. 
However, the study also has some limitations. First, although a variety of patient-related 
predictors were included, other patient-related or treatment-process predictors could not 
be tested. As pointed out by Brorson et al,14 treatment factors such as treatment setting 
and duration and treatment process factors such as treatment alliance may also be of 
high relevance for drop-out and deserve more attention in future research. Second, since 
abstinence was not required in this study, participants might have been (mildly) intoxicated 
with alcohol or drugs during the assessments, which could have influenced the results of 
the cognitive tasks in particular. However, we administered the diagnostic assessment of 
ADHD during active substance use and during abstinence and found very similar results.56 
Third, we did not correct for multiple testing because of insufficient sample size; this could 
have induced Type I errors. Fourth, the current study did not provide tangible rewards for 
the BART performance, which might have influenced the results. Lastly, the effect size of the 
treatment results we found in the RCT were modest, suggesting that further improvement 
in the treatment of this complex comorbid patient group is still needed.
Our findings are of direct clinical relevance. As many patients drop out from addiction 
treatment in an early phase, and predictors for drop-out are known, patients who are at risk 
for early drop-out should be identified by a screening procedure and offered alternative or 
additional interventions. More specifically, this includes interventions that do not require as 
much of the attention, memory, and planning functions as traditional therapies. Contingency 
management, for instance, has lower drop-out rates than traditional treatments57 and 
could be used in combination with traditional therapy. Furthermore, several interventions 
to improve neurocognitive functioning have been designed and although research on this 
topic is limited, positive results also on treatment outcomes have been reported.58 More 
research on alternative interventions to enhance treatment retention is paramount. 
Finally, our finding that the benefit of CBT/Integrated was not restricted to a specific 
subgroup of patients, allows for a broader dissemination of this treatment for SUD patients 
with comorbid ADHD. 
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